<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00357149</url>
  </required_header>
  <id_info>
    <org_study_id>XRP6976F_2501</org_study_id>
    <nct_id>NCT00357149</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Patients (SCCHNS)</brief_title>
  <official_title>Randomized Phase II Trial of Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To evaluate the rate of clinical complete response 6-8 weeks after treatment with docetaxel&#xD;
      plus cisplatin and 5-fluorouracil followed by chemoradiotherapy and after chemoradiotherapy&#xD;
      alone in patients with locally advanced squamous cell carcinoma of the head and neck.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of radiologic Complete Response (CR) evaluated 6-8 weeks after the completion of treatment</measure>
    <time_frame>from end of treatment until 6-8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>from the date of first documented tumor response to the date of first documented tumor progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression</measure>
    <time_frame>From the date of the treatment start to the date of first documented progression of disease</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>from the date of treatment start to the date of diagnosis of progression, withdrawal from study treatment for any reason, administration of other antitumor treatment, or death for any cause</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median length of overall survival</measure>
    <time_frame>time interval from the date of treatment to the date of death</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cisplatin from day 1 to day 4 and 5-FU for 4 days starting immediately after the end of cisplatin infusion on day 1. Both drugs were administered during week 1 and 6 of irradiation, starting from day 1 of weekly radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel followed by cisplatin and 5-FU from day 1 to day 4 starting after the end of cisplatin infusion. The cycle was repeated every 3 weeks up to a total of 3 cycles. After 3-6 weeks from the end of neoadjuvant chemotherapy, patients will receive with the same modality of arm A (reference arm).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapy</intervention_name>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Concomitant cisplatin, 5-FU and radiotherapy</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Histologically or cytologically proven squamous cell carcinoma of the head and neck.&#xD;
&#xD;
          -  Primary tumor sites eligible: oral cavity, oropharynx, hypopharynx. Although they are&#xD;
             admittedly of squamous cell types, the following tumors will be excluded because of&#xD;
             theY responsiveness to chemotherapy: tumors of the nasal and paranasal cavities,&#xD;
             larynx and of the nasopharynx.&#xD;
&#xD;
          -  Stage III or IV disease without evidence of distant metastases verified by chest X Ray&#xD;
             and/or lung CT scan, abdominal ultrasound, or CT (liver function test abnormalities);&#xD;
             bone scan in case of local symptoms.&#xD;
&#xD;
          -  At least one measurable lesion.&#xD;
&#xD;
          -  Tumor considered inoperable after evaluation by a multidisciplinary team (i.e. a&#xD;
             surgeon, a medical oncologist and a radiation oncologist).&#xD;
&#xD;
          -  No previous chemotherapy or radiotherapy for any reason and no previous surgery for&#xD;
             squamous cell carcinoma of the head and neck patients (other than biopsy) are allowed&#xD;
             at time of study entry.&#xD;
&#xD;
          -  Karnofsky performance status ≥ 70.&#xD;
&#xD;
          -  No active alcohol addiction.&#xD;
&#xD;
          -  Adequate bone marrow, hepatic and renal functions&#xD;
&#xD;
          -  Patients must be available for treatment and follow-up.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Pregnant or lactating women or women of childbearing potential not using adequate&#xD;
             contraception.&#xD;
&#xD;
          -  Previous or current malignancies at other sites, with the exception of adequately&#xD;
             treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma of the&#xD;
             skin, or other cancer curatively treated by surgery and with no evidence of disease&#xD;
             for at least 5 years.&#xD;
&#xD;
          -  Symptomatic peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  Symptomatic altered hearing ≥ grade 2&#xD;
&#xD;
          -  Other serious illnesses or medical conditions including:a) Unstable cardiac disease&#xD;
             despite treatment, myocardial infarction within 6 months prior to study entry.b)&#xD;
             History of significant neurologic or psychiatric disorders including dementia or&#xD;
             seizures.c) Active uncontrolled infection.d) Active peptic ulcer.e) Hypercalcemia.f)&#xD;
             Chronic obstructive pulmonary disease requiring hospitalization during the year&#xD;
             preceding study entry&#xD;
&#xD;
          -  History of hypersensitivity reaction to polysorbate 80&#xD;
&#xD;
          -  Patients requiring intravenous alimentation.&#xD;
&#xD;
          -  Patients who experienced a weight loss of more than 20% of their body weight in the 3&#xD;
             months preceding study entry.&#xD;
&#xD;
          -  Concomitant treatment with any other anticancer therapy.&#xD;
&#xD;
          -  Participation in a therapeutic clinical trial within 30 days of study entry&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georges Paizis, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>July 26, 2006</study_first_submitted>
  <study_first_submitted_qc>July 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2006</study_first_posted>
  <last_update_submitted>December 4, 2009</last_update_submitted>
  <last_update_submitted_qc>December 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

